Payors In Ranbaxy MDL Lose 2 State Claims On Notice Rules
A Massachusetts federal judge on Friday cut a pair of state claims from a suit by health care plans and consumers accusing Ranbaxy Pharmaceuticals of gaming the generic-drug approval system, finding...To view the full article, register now.
Already a subscriber? Click here to view full article